6533b86dfe1ef96bd12c95f0

RESEARCH PRODUCT

Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study

V. SerrettaCarlo PavoneMichele Pavone-macalusoB. PiazzaS. Piazza

subject

medicine.medical_specialtyPathologyUrologyUrologyPhases of clinical researchlaw.inventionlawRecurrencemedicineHumansPapillary transitional cell carcinomaCarcinoma Transitional Cellbusiness.industryTumor Necrosis Factor-alphaRecombinant ProteinRecombinant ProteinsRecombinant Tumor Necrosis Factor-AlphaIntravesical treatmentAdministration IntravesicalTolerabilityUrinary Bladder NeoplasmsToxicityRecombinant DNATumor necrosis factor alphabusinessHuman

description

Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent. Int J Urol 1995;2:100-103

yearjournalcountryeditionlanguage
1995-05-01
10.1111/j.1442-2042.1995.tb00433.xhttp://hdl.handle.net/10447/356860